APPIA BIO
Innovating Cell Therapy
TEAM
We collaborate across a diversity of disciplines, which is critical to developing next-generation therapies for patients.
OUR TECHNOLOGY
With our ACUA technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs). Our research and development efforts are focused on engineered allogeneic cell therapies with a scalable technology platform to increase therapeutic options and availability for patients.
MEDIA & PRESS UPDATES
APPIA BIO ANNOUNCES APPOINTMENT OF IRVING WEISSMAN, MD AND MARK EXLEY, PHD TO SCIENTIFIC ADVISORY BOARD
December 1, 2021
KITE AND APPIA BIO ANNOUNCE COLLABORATION FOR ALLOGENEIC CELL THERAPIES FOR CANCER
August 5, 2021
APPIA BIO NAMES CELL THERAPY MANUFACTURING VETERAN QI WEI, PHD AS SENIOR VICE PRESIDENT OF TECHNICAL OPERATIONS
May 19, 2021
APPIA BIO LAUNCHES WITH $52 MILLION SERIES A FINANCING AND ESTABLISHES SCIENTIFIC ADVISORY BOARD
May 11, 2021
JOIN US
We’re a growing early-stage biotechnology company. We're looking for talented people who are passionate about innovating new medicines at the cutting-edge of science. See our job listings at:
https://www.linkedin.com/company/appiabio/jobs/
6160 Bristol Parkway #300 Culver City, CA 90230